For how we live.
Approved 9 November, asundexian is cleared alongside antiplatelet therapy to lower ischaemic stroke risk after a non-cardioembolic stroke or high-risk TIA. In a 12,327-patient trial it cut that risk by 26%.
In a 300-patient Chinese trial, endovascular therapy left far more people with mild large-vessel stroke free of meaningful disability at 90 days than medication alone, but serious procedural complications were common.
LATE-MT randomly assigned 336 patients with salvageable brain tissue to thrombectomy or standard care 24 to 72 hours after a large-vessel stroke. Clot removal cut disability at 90 days but raised brain bleeds and death.
A detailed safety analysis of the 12,254-patient OCEANIC-STROKE trial found no significant rise in major bleeding with the factor XI blocker, though lower gastrointestinal bleeding was more frequent.
Face, arm, speech, time is the message that saves lives. But in one US stroke centre 14% of ischaemic strokes had no FAST sign at all — and every minute of delay costs an estimated 1.9 million neurons.
LIBREXIA-ACS enrolled 14,194 patients before stopping for futility. Milvexian did not reduce events, but intracranial and fatal bleeding were identical to placebo, which is the class's whole premise.
In ATTRACTION, tirofiban given after successful thrombectomy left more stroke patients independent at 90 days than placebo, though symptomatic brain bleeds trended higher and were not significantly different.
England ran the closest thing to a national test of clinical AI anyone has published. The software sites gained more, but the comparison sites were improving on their own, and that gap is the whole result.